William L. Klein

Q: What Schools Are Affiliated With William L. Klein

William L. Klein is affiliated with the following schools: University of California, Berkeley, Northwestern University, University of California, Los Angeles, Stanford University, Massachusetts Institute of Technology, Colorado State University

William L. Klein's AcademicInfluence.com Rankings

William L. Klein

Biology

#9694

World Rank

#12927

Historical Rank

Neuroscience

#1429

World Rank

#1479

Historical Rank

biology Degrees

Download Badge

Biology

William L. Klein's Degrees

PhD Neurobiology Stanford University
Masters Biology Stanford University
Bachelors Biology Stanford University

Similar Degrees You Can Earn

Why Is William L. Klein Influential?

(Suggest an Edit or Addition)

(See a Problem?)

William L. Klein's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. (1998) (3525)
Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss (2003) (1081)
Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? (2001) (1024)
Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease (2007) (984)
Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* (2007) (850)
Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers (2004) (824)
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. (2005) (778)
Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. (2005) (765)
An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. (2012) (701)
Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. (2013) (661)
A Localized Surface Plasmon Resonance Biosensor: First Steps toward an Assay for Alzheimer's Disease (2004) (624)
Amyloid beta oligomers induce impairment of neuronal insulin receptors (2008) (566)
Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers (2009) (563)
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. (2007) (536)
Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer’s disease (2004) (510)
Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus (2002) (500)
Aβ toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets (2002) (491)
Synaptic targeting by Alzheimer's-related amyloid beta oligomers. (2004) (489)
Self-assembly of Aβ1-42 into globular neurotoxins (2003) (456)
Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis (2015) (442)
Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5 (2010) (432)
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade (2018) (416)
Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers (2008) (375)
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) (370)
A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo (2010) (359)
Cholesterol Modulates -Secretase Cleavage of Amyloid Precursor Protein (*) (1996) (355)
Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease (2006) (348)
Amyloid-β-Induced Pathological Behaviors Are Suppressed by Ginkgo biloba Extract EGb 761 and Ginkgolides in Transgenic Caenorhabditis elegans (2006) (336)
Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies (2001) (335)
TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys. (2013) (327)
Monoclonal antibodies that target pathological assemblies of Aβ (2007) (326)
D1-type dopamine receptors inhibit growth cone motility in cultured retina neurons: evidence that neurotransmitters act as morphogenic growth regulators in the developing central nervous system. (1988) (281)
Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. (2002) (271)
Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1 (2006) (258)
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model (2008) (241)
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. (2006) (232)
Selective neuronal degeneration induced by soluble oligomeric amyloid beta‐protein (2003) (215)
Self-assembly of Abeta(1-42) into globular neurotoxins. (2003) (208)
Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo (2011) (199)
Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice (2008) (199)
Decreased Brain-Derived Neurotrophic Factor Depends on Amyloid Aggregation State in Transgenic Mouse Models of Alzheimer's Disease (2009) (189)
Alzheimer's Disease-Like Pathology Induced by Amyloid-β Oligomers in Nonhuman Primates (2014) (183)
A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. (2010) (176)
Alzheimer-associated Aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation (2015) (168)
Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. (1996) (163)
CANNABIS: AN EXAMPLE OF TAXONOMIC NEGLECT (1974) (162)
Memantine Rescues Transient Cognitive Impairment Caused by High-Molecular-Weight Aβ Oligomers But Not the Persistent Impairment Induced by Low-Molecular-Weight Oligomers (2013) (153)
Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. (2008) (153)
The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non‐human primate model of Alzheimer's disease (2018) (153)
N‐Methyl‐d‐aspartate receptors are required for synaptic targeting of Alzheimer’s toxic amyloid‐β peptide oligomers (2010) (150)
Towards Non-Invasive Diagnostic Imaging of Early-Stage Alzheimer’s Disease (2014) (147)
Intraneuronal aggregation of the β-CTF fragment of APP (C99) induces Aβ-independent lysosomal-autophagic pathology (2016) (147)
Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. (2009) (141)
Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer's disease. (2015) (137)
Aβ Oligomer-Induced Synapse Degeneration in Alzheimer’s Disease (2011) (133)
Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. (2009) (131)
NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer’s Disease (2018) (130)
Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ* (2009) (130)
Salvianolic acid B inhibits Aβ fibril formation and disaggregates preformed fibrils and protects against Aβ-induced cytotoxicty (2008) (126)
Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? (2012) (124)
Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease (2012) (120)
The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. (2009) (116)
Cholinergic activity regulates muscarinic receptors in central nervous system cultures. (1979) (114)
ADDLs and the signaling web that leads to Alzheimer’s disease (2010) (112)
Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity (2012) (110)
Microtubule-Associated Protein Tau Is Hyperphosphorylated during Mitosis in the Human Neuroblastoma Cell Line SH-SY5Y (1994) (109)
CCL2 Accelerates Microglia-Mediated Aβ Oligomer Formation and Progression of Neurocognitive Dysfunction (2009) (108)
FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer's disease. (2013) (105)
Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer’s disease (2006) (104)
Why Alzheimer’s is a disease of memory: The attack on synapses by Aß oligomers (ADDLs) (2008) (102)
Muscarinic acetylcholine receptor regulation by accelerated rate of receptor loss. (1979) (102)
Regulation of adenylate cyclase activity mediated by muscarinic acetylcholine receptors. (1978) (96)
Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers. (2016) (94)
Endoplasmic reticulum stress occurs downstream of GluN2B subunit of N‐methyl‐D‐aspartate receptor in mature hippocampal cultures treated with amyloid‐β oligomers (2012) (91)
Focal adhesion kinase expressed by nerve cell lines shows increased tyrosine phosphorylation in response to Alzheimer's A beta peptide. (1994) (90)
Intraneuronal amyloid-beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo (2011) (90)
A transient embryonic dopamine receptor inhibits growth cone motility and neurite outgrowth in a subset of avian retina neurons (1987) (87)
Regulation of Muscarinic Acetylcholine Receptor Concentration in Cloned Neuroblastoma Cells (1980) (86)
Amyloid-β Triggers the Release of Neuronal Hexokinase 1 from Mitochondria (2010) (83)
Regulation of dopamine- and adenosine-dependent adenylate cyclase systems of chicken embryo retina cells in culture. (1982) (81)
Iron Levels Modulate α‐Secretase Cleavage of Amyloid Precursor Protein (1995) (78)
Inhibition of Choline Acetyltransferase as a Mechanism for Cholinergic Dysfunction Induced by Amyloid-β Peptide Oligomers* (2012) (77)
ADDLs & protofibrils—the missing links? (2002) (77)
Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study (2014) (76)
Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer’s pathology (2017) (75)
Comparative binding studies with cholinergic ligands and histrionicotoxin at muscarinic receptors of neural cell lines. (1978) (75)
Femtomole immunodetection of synthetic and endogenous amyloid-β oligomers and its application to Alzheimer’s disease drug candidate screening (2007) (74)
Amyloid-β and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. (2012) (74)
β/A4‐evoked degeneration of differentiated SH‐SY5Y human neuroblastoma cells (1994) (74)
Interaction of beta-amyloid peptides with integrins in a human nerve cell line (1995) (70)
Plasticity of neuronal receptors (1989) (67)
Hypercholesterolemia accelerates intraneuronal accumulation of Aβ oligomers resulting in memory impairment in Alzheimer's disease model mice. (2012) (63)
Conformation‐dependent single‐chain variable fragment antibodies specifically recognize beta‐amyloid oligomers (2009) (60)
Nanodisc-solubilized membrane protein library reflects the membrane proteome (2013) (55)
AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice. (2009) (55)
Visualization of co-localization in Aβ42-administered neuroblastoma cells reveals lysosome damage and autophagosome accumulation related to cell death. (2012) (54)
Phosphorylated Tau Epitope of Alzheimer's Disease Is Coupled to Axon Development in the Avian Central Nervous System (1993) (53)
Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain (2020) (52)
Differential ontogenesis of D1 and D2 dopaminergic receptors in the chick embryo retina. (1984) (51)
Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice. (2013) (51)
Protection against the synaptic targeting and toxicity of Alzheimer's‐associated Aβ oligomers by insulin mimetic chiro‐inositols (2013) (50)
Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound Aβ oligomers (2017) (49)
Disruption of neocortical histone H3 homeostasis by soluble Aβ: implications for Alzheimer's disease (2013) (49)
Detection and Identification of Bioanalytes with High Resolution LSPR Spectroscopy and MALDI Mass Spectrometry. (2009) (48)
Heat shock treatment reduces beta amyloid toxicity in vivo by diminishing oligomers (2010) (48)
Protein kinase C and F‐actin are essential for stimulation of neuronal FAK tyrosine phosphorylation by G‐proteins and amyloid beta protein (1996) (47)
Amyloid-β oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons (2017) (47)
Cyclic AMP enhancers and Abeta oligomerization blockers as potential therapeutic agents in Alzheimer's disease. (2007) (43)
Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers (2010) (43)
Two molecular weight forms of muscarinic acetylcholine receptors in the avian central nervous system: switch in predominant form during differentiation of synapses. (1985) (42)
Reversible Inactivation of Superoxide‐Sensitive Aconitase in Aβ1‐42‐Treated Neuronal Cell Lines (2000) (42)
Transgenic mice as a model of pre-clinical Alzheimer's disease. (2011) (41)
PGH2‐derived levuglandin adducts increase the neurotoxicity of amyloid β1–42 (2006) (41)
Salvianolic acid B inhibits Abeta fibril formation and disaggregates preformed fibrils and protects against Abeta-induced cytotoxicty. (2008) (40)
Synapse-binding subpopulations of Aβ oligomers sensitive to peptide assembly blockers and scFv antibodies. (2012) (39)
Receptor‐Mediated Increases in Phosphatidylinositol Turnover in Neuron‐Like Cell Lines (1983) (39)
CNS neuronal focal adhesion kinase forms clusters that co‐localize with vinculin (1996) (38)
Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease (2019) (38)
Aβ peptide enhances focal adhesion kinase/Fyn association in a rat CNS nerve cell line (1996) (38)
Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes (2016) (36)
Beta/A4-evoked degeneration of differentiated SH-SY5Y human neuroblastoma cells. (1994) (34)
Differentiation of neuronal growth cones: specialization of filopodial tips for adhesive interactions. (1985) (34)
Per-6-substituted-per-6-deoxy β-cyclodextrins Inhibit the Formation of β-Amyloid Peptide Derived Soluble Oligomers (2004) (34)
Parallel Postnatal Development of Choline Acetyltransferase Activity and Muscarinic Acetylcholine Receptors in the Rat Olfactory Bulb (1986) (32)
Nanoscale Synaptic Membrane Mimetic Allows Unbiased High Throughput Screen That Targets Binding Sites for Alzheimer’s-Associated Aβ Oligomers (2015) (32)
Molecular alteration of a muscarinic acetylcholine receptor system during synaptogenesis. (1985) (32)
Delivery of membrane-impermeant fluorescent probes into living neural cell populations by lipotransfer (1996) (31)
Modulation of Amyloid‐β Aggregation by Histidine‐Coordinating Cobalt(III) Schiff Base Complexes (2014) (30)
Specificity of Muscarinic Acetylcholine Receptor Regulation by Receptor Activity (1981) (30)
Neuroprotective astrocyte-derived insulin/IGF-1 stimulate endocytic processing and extracellular release of neuron-bound Aβ oligomers. (2017) (28)
Ultrastructural networks in growth cones and neurites of cultured central nervous system neurons. (1983) (28)
Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. (2009) (28)
Occurrence of muscarinic acetylcholine receptors in wild type and cholinergic mutants of Caenorhabditis elegans (1983) (28)
l-Glutamate evoked release of GABA from cultured avian retina cells does not require glutamate receptor activation (1988) (27)
Erratum: Protection of synapses against Alzheimer's- Linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers (Proceedings of the National Academy of Sciences of the United States of America (2009) 106 (1971-1976) DOI:10.1073/pnas.0809158106) (2009) (26)
Glycoprotein Properties of Muscarinic Acetylcholine Receptors from Bovine Cerebral Cortex (1986) (26)
Molecules that Disrupt Memory Circuits in Alzheimer’s Disease: The Attack on Synapses by Aβ Oligomers (ADDLs) (2007) (26)
The systematics and evolution of the Oenothera caespitosa species complex (Onagraceae) (1985) (26)
Elucidating Molecular Mass and Shape of a Neurotoxic Aβ Oligomer (2014) (26)
Evidence that small molecule enhancement of β-hexosaminidase activity corrects the behavioral phenotype in Dutch APPE693Q mice through reduction of ganglioside-bound Aβ (2014) (24)
alpha-Bungarotoxin receptors on neurons isolated from turtle retina: molecular heterogeneity of bipolar cells (1985) (24)
Alzheimer’s Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station (2017) (24)
A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid‐β oligomers (2017) (23)
Multiple binding states of muscarinic acetylcholine receptors in membranes from neuroblastoma x glioma hybrid cells. (1980) (23)
Differential regulation of muscarinic and nicotinic receptors by cholinergic stimulation in cultured avian retina cells (1983) (22)
Per-6-substituted β-cyclodextrin libraries inhibit formation of β-amyloid-peptide (Aβ)-derived, soluble oligomers (2002) (22)
Cellular mapping of m2 muscarinic receptors in rat olfactory bulb using an antiserum raised against a cytoplasmic loop peptide (1991) (22)
Accumulation of intraneuronal amyloid-β is common in normal brain. (2014) (21)
Rapid impact of β‐amyloid on Paxillin in a neural cell line (1997) (20)
Selective Expression of Factors Preventing Cholinergic Dedifferentiation (1990) (20)
Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer’s disease (2022) (20)
Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer’s APP/PSEN1 mice by gene targeting of diabetes/Alzheimer’s-related Sorcs1 (2016) (20)
D1-type dopamine receptors inhibit growth cone motility in cultured retina neurons: evidence that neurotransmitters act as morphogenic growth regulators in the developing central nervous system. (1988) (20)
Constitutive Alzheimer's-type tau epitopes in a neuritogenic rat CNS cell line (1995) (19)
Alzheimer's-associated phospho-tau epitope in human neuroblastoma cell cultures: Up-regulation by fibronectin and laminin (1995) (18)
Soluble state high resolution atomic force microscopy study of Alzheimer's beta-amyloid oligomers. (2009) (18)
Vegetation of Amchitka Island, Aleutian Islands, Alaska (1969) (18)
A novel crosslinking protocol stabilizes amyloid β oligomers capable of inducing Alzheimer's‐associated pathologies (2019) (17)
Identification of intraneuronal amyloid beta oligomers in locus coeruleus neurons of Alzheimer’s patients and their potential impact on inhibitory neurotransmitter receptors and neuronal excitability (2020) (17)
Free-floating adult human brain-derived slice cultures as a model to study the neuronal impact of Alzheimer’s disease-associated Aβ oligomers (2018) (17)
Muscarinic acetylcholine receptor binding in the guinea pig cochlea (1983) (17)
THE EVOLUTION OF THREE DIPLOID SPECIES OF OENOTHERA SUBGENUS ANOGRA (ONAGRACEAE) (1970) (16)
Investigations of Meiotic Chromosomes of Six Genera in the Onagraceae (1960) (15)
Neuronal amyloid- b accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease (2015) (15)
Cytotoxic Intermediates in the Fibrillation Pathway: Aβ Oligomers in Alzheimer’s Disease as a Case Study (2006) (14)
Biochemistry and regulation of signal transduction by neuronal acetylcholine receptors. (1984) (14)
Control of Cherry Leaf Spot and Powdery Mildew on Sour Cherry with Alternate-Side Applications of Fenarimol, Myclobutanil, and Tebuconazole (1993) (14)
AAV1/2-mediated CNS Gene Delivery of Dominant-negative CCL2 Mutant Suppresses Gliosis, β-amyloidosis, and Learning Impairment of APP/PS1 Mice. (2009) (14)
Developmentally Regulated Secreted Factors Control Expression of Muscarinic Receptor Subtypes in Embryonic Chick Retina (1993) (13)
Dl-type dopamine receptors inhibit growth cone motility in cultured retina neurons: Evidence that neurotransmitters act as morphogenic growth regulators in the developing central nervous system (13)
Ultrastructure of individual neurons isolated from avian retina: occurrence of microtubule loops in dendrites. (1990) (12)
Rapid impact of beta-amyloid on paxillin in a neural cell line. (1997) (11)
A Study of Aβ Oligomers in the Temporal Cortex and Cerebellum of Patients with Neuropathologically Confirmed Alzheimer's Disease Compared to Aged Controls (2016) (11)
7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (2001) (11)
Soluble proteins from rat olfactory bulb promote the survival and differentiation of cultured basal forebrain neurons. (1988) (11)
Molecular basis of growth cone adhesion: anchoring of adheron- containing filaments at adhesive loci (1988) (11)
Per-6-substituted beta-cyclodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-derived, soluble oligomers. (2002) (10)
Muscarinic Acetylcholine Receptors from Avian Retina and Heart Undergo Different Patterns of Molecular Maturation (1988) (10)
Regulation of muscarinic acetylcholine receptors. (1980) (10)
Particulate forms of APP in the extracellular milieu of cultured cells (1995) (10)
D 1-type dopamine receptors inhibit growth cone motility in cultured retina neurons : Evidence that neurotransmitters act as morphogenic growth regulators in the developing central nervous system ( axon / dendrite / synapse ) (10)
Autoradiography of dendritic acetylcholine receptors: A method for study of isolated neurons of the adult central nervous system in the turtle (1982) (10)
Induction of inverted morphology in brain organoids by vertical-mixing bioreactors (2021) (9)
Autonomous control of phosphatidylinositol turnover by histamine and acetylcholine receptors in the N1E-115 neuron-like cell line (1986) (9)
Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers. (2004) (9)
Succinylation Links Metabolic Reductions to Amyloid and Tau Pathology (2019) (8)
Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers (2020) (8)
Alkaloids of Argemone glauca var. glauca (1971) (8)
Kalirin‐7 prevents dendritic spine dysgenesis induced by amyloid beta‐derived oligomers (2019) (8)
New Taxa and Recombinations in Oenothera (Anogra) (1962) (8)
Why Alzheimer’s is a Disease of Memory: Synaptic Targeting by Pathogenic Aβ Oligomers (ADDLs) (2008) (7)
Potential βPP-processing proteinase activities from alzheimer's and control brain tissues (1994) (7)
AAV 1 / 2-mediated CNS Gene Delivery of Dominant-negative CCL 2 Mutant Suppresses Gliosis , β-amyloidosis , and Learning Impairment of APP / PS 1 Mice (7)
Vegetation of Amchitka Island, Aleutian Islands, Alaska. Geological survey professional paper 648 (1969) (7)
Cleavage of fluorogenic substrates for APP-processing proteases by human brain extracts. Ca(2+)-substrate interaction is responsible for Ca2+ stimulation of the neural protease activity. (1994) (7)
Alkaloids of Argemone fruticosa and A. echinata (1973) (7)
Environmental Inventory and Assessment of Navigation Pools 24, 25, and 26, Upper Mississippi and Lower Illinois Rivers: A Vegetational Study. (1975) (6)
Evidence Against a Role for the Kunitz Domain in Amyloidogenic and Secretory Processing of the Amyloid Precursor Protein (1994) (6)
Insights into the mechanism of Alzheimer’s β-amyloid aggregation as a function of concentration by using atomic force microscopy (2012) (6)
Aβ oligomer induced cognitive impairment and evaluation of ACU193‐MNS‐based MRI in rabbit (2020) (5)
Aβ Oligomers-Induced Toxicity is Attenuated in Cells Cultured with NbActiv4™ Medium (2012) (4)
Biochemical differentiation of nascent neurite junctions: unilateral localization of adheron components. (1990) (4)
Intrathecal amyloid‐beta oligomer administration increases tau phosphorylation in the medial temporal lobe in the African green monkey: A nonhuman primate model of Alzheimer's disease (2022) (4)
Fluorescent and Scanometric Ultrasensitive Detection Technologies with the Bio-Bar Code Assay for Alzheimer's Disease Diagnosis (2005) (3)
Transient expression of adheron molecules during chick retinal development. (1992) (3)
Inhibition of choline acetyltransferase as a mechanism for cholinergic dysfunction induced by amyloid-β oligomers (2012) (3)
An Essential Role for Alzheimer’s-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis (2022) (3)
P3-319 Synaptic targeting by Alzheimer's related abeta oligomers (2004) (3)
Soluble Abeta oligomers (ADDLs) in Alzheimer’s disease memory loss, therapeutics, and diagnostics (2005) (2)
Gardens of Philadelphia & the Delaware Valley (1995) (2)
Biological Targeting and Activity of Pre-fibrillar Aβ Assemblies (2012) (2)
Efficient Gene Silencing in Neural Cells by Functionalized Gold Nanoparticles (2010) (2)
The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer’s Disease (2022) (2)
PHYTOPHAGOUS HETEROPTERA AND IFP - A SOLVABLE CONTRADICTION? (1996) (2)
AN INFLAMMATORY PATHWAY TOWARD SYNAPSE AND COGNITIVE IMPAIRMENT TRIGGERED BY AMYLOID-BETA OLIGOMERS: NOVEL MOLECULAR LINKS BETWEEN ALZHEIMER'S DISEASE AND DIABETES (2014) (1)
Differential impact of high and low molecular mass beta-amyloid oligomers on synapse density, receptor composition and memory in mice (2013) (1)
Localization of muscarinic receptors and cholinesterase on cultured chick retinal cells (1981) (1)
Mid-range molecular weight oligomers in the normal and Alzheimer brain: Clinico-pathological correlations (2014) (1)
Endoplasmic reticulum stress links impaired insulin signaling and Alzheimer's disease (2012) (1)
Intranasal passive immunization using WGA-modified oligomer antibodies greatly improves learning and memory in Alzheimer's 5XFAD mice (2012) (1)
Diet‐induced Alzheimer's‐like syndrome in the rabbit (2022) (1)
Cholinergic differentiation in neurogenic basal forebrain cultures. (1992) (1)
P2-324: ICV anti-ADDL antibody prevented early synaptic deficits in TgCRND8 mouse model of Alzheimer's disease (2008) (1)
Rapid recovery of nicotinic receptor-mediated sodium-22 influx following withdrawal from acute or chronic cholinergic stimulation (1982) (1)
LINING CONCEPTIONS FOR LADLES USED IN SECONDARY METALLURGY BASED ON SPECIFIC PROPERTIES OF REFRACTORY MATERIALS (1991) (1)
STRUCTURE AND EXPRESSION OF THE SEA URCHIN SPEC GENES (1987) (1)
Increased protein tyrosine phosphorylation in apoptotic neural cell death due to microtubule perturbations (2000) (1)
Modeling Alzheimer's disease using iPS cells reveals stress phenotypes associated with intracellular beta-amyloid oligomer and differential drug responsiveness (2013) (1)
Partial Suppression of Ca v2.1 Function Prevents Synaptic and Behavioral Impairments in Alzheimer's Disease Models (2020) (1)
AAV-mediated neuronal expression of a scFv antibody selective for Aβ oligomers protects synapses and rescues memory in Alzheimer models (2022) (1)
SMPL Synaptic Membranes: Nanodisc-Mediated Synaptic Membrane Mimetics Expand the Toolkit for Drug Discovery and the Molecular Cell Biology of Synapses (2018) (1)
Muscarinic acetylcholine receptors of cells and homogenates from turtle and cat retina (1980) (1)
Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study (2014) (1)
Neuronal expression of NUsc1, a single-chain variable fragment antibody against Ab oligomers, protects synapses and rescues memory in Alzheimer's disease models (2019) (1)
Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer’s disease (2022) (0)
Intraneuronal accumulation of Aβ oligomers causes abnormal tau phosphorylation, glial activation and neuronal loss in transgenic mice with APP E693Δ mutation (2010) (0)
P.5.a.004 Trasient receptor potential ankyrin 1 (TRPA1): a novel relevant target in Alzheimer's disease? (2015) (0)
PrP — A piece of the puzzle, but where does it fit? (2014) (0)
Hypercholesterolemia accelerates memory impairment in a transgenic mouse model of Abeta oligomers (2010) (0)
Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer’s APP/PSEN1 mice by gene targeting of diabetes/Alzheimer’s-related Sorcs1 (2016) (0)
Soluble Aβ Oligomers in Alzheimer’s Disease (2008) (0)
Oligomeric and Fibrillar Amyloid-beta42 Studied by Cryo-TEM (2009) (0)
10. The Role of Botanical Gardens and Arboreta in Traditional Medicine: A Personal Reflection and Case Study (1998) (0)
Contents Vol. 16, 2016 (2016) (0)
Neuronal expression of a single‐chain variable fragment antibody against Aβ oligomers protects synapses and rescues memory in Alzheimer models (2020) (0)
An ultrasensitive immunoassay detects soluble Aβ oligomers in tg mice prior to memory loss (2015) (0)
Cotyledon Variations in Juniperus Occidentalis Hook (1958) (0)
LONGITUDINAL COGNITIVE PERFORMANCE IN THE OLDEST OLD WITH NO DEMENTIA: A-BETA OR OTHER PATHOLOGIES? (0)
Identification of amyloid beta oligomers in locus coeruleus (LC) neurons of Alzheimer’s patients and their impact on LC oxidative stress, inhibitory neurotransmitter receptors and neuronal excitability (2020) (0)
Modeling Alzheimer's disease using induced pluripotent stem cells from familial and sporadic Alzheimer's disease patients (2013) (0)
Different distribution of soluble beta-amyloid assemblies in the Tg2576 mouse brain and Alzheimer disease autopsy brain (2011) (0)
A nonhuman primate model of Alzheimer's disease with tangles and synapse loss triggered by Aß oligomers (2012) (0)
Amyloid β oligomer selective antibodies for Alzheimer’s therapeutics and diagnostics (2021) (0)
Characterization of Anti-ADDL Antibodies for Use in Tandem LSPR-MALDI Investigation of Alzheimer's Disease Brain Extracts (2009) (0)
Synapse disruption in AD brain: Evidence for early pathological clustering of the group I metabotropic glutamate receptor 5 (2011) (0)
Synaptotoxicity of Abeta oligomers results from “hijacking” of metabotropic glutamate receptors (2010) (0)
Histological localization of amyloid-β oligomers in the human brain during the course of Alzheimer's disease (2011) (0)
P1-086: Intracellular accumulation of Aβ oligomers and inflammatory response precede plaque formation in a new transgenic model of the Alzheimer-like amyloid pathology (2008) (0)
Alzheimer Retina Pathology in a Novel Animal Model of Neuropathology in Diabetes (2012) (0)
41 Is tau phosphorylation the fuse and toxic Abeta the match? (2012) (0)
Collaborative Research: failure of RockMasses from Nucleation and Growth of Microscopic Defects and Disorder (2016) (0)
Porous carbon-ceramic blends durability with quality (1999) (0)
Commentary ADDLs & protofibrils —the missing links? (2002) (0)
Anti-diabetic drugs protect the brain from defective insulin signaling caused by Alzheimer's toxic Aß oligomers (2012) (0)
Utilizing the Scanometric Immunoassay for the Ultrasensitive Detection of Aβ-42 Oligomers for the Early Detection of Alzheimer's Disease (2010) (0)
Muscarinic Acetylcholine Receptors in Developing Chick Heart 8693 (2002) (0)
The therapeutic and diagnostic potential of amyloid β oligomers ( A β Os ) 1 selective antibodies to treat Alzheimer ' s disease 2 Running title : A β O-antibodies for therapeutics and diagnostics 3 (2021) (0)
P4-263: Insulin prevents the pathological impact of soluble Abeta oligomers on neuronal insulin receptors (2008) (0)
A transgenic mouse model of amyloid β oligomers: Pathological effects of the E693Δ mutation in amyloid precursor protein in vivo (2009) (0)
Aβ oligomers impair neuronal insulin signaling (2010) (0)
Globular structure of the amyloid beta protein and their uses (2000) (0)
A time for optimism in the dementia field (2022) (0)
Targeting Aß oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer’s disease (2014) (0)
NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer’s Disease (2017) (0)
Workshop W3: Old and New Players in Myelin Assembly (2004) (0)
Beta amyloid protein (globular assembly and their uses). (1998) (0)
Solvent Effects on the Kinetics of Amyloid-b Oligomerization (2007) (0)
CHARACTERIZATION OF DIFFERENT AΒ OLIGOMER ASSEMBLIES IN ALZHEIMER AUTOPSY BRAIN TISSUE (2011) (0)
Molecular weight 72000 and molecular weight 86000 forms of muscarinic acetylcholine receptors in avian central nervous system shift in predominant form during development (1985) (0)
Amyloid beta-derived dementing ligands for treating cancer, whose modulators are useful in treating learning, memory disorders, has amyloid beta-protein assembled into globular non-fibrillar oligomeric structures (2012) (0)
Immunolocalization of oligomeric Abeta42 binding to primary mouse hippocampal cells and B103 rat neuroblastoma cells (1999) (0)
Aβ Oligomers-Induced Toxicity is Attenuated in Cells Cultured with NbActiv4™ Medium (2012) (0)
Liraglutide protects the brains of macaques against synapse loss caused by abeta oligomers (2015) (0)
P1-490: An essential role for kalirin-7 in soluble oligomeric amyloid-induced spine dysfunction (2008) (0)
globular amyloid beta protein assembly and its uses. (2000) (0)
NON-TRANSGENIC DIETARY-INDUCED MODELS OF AD-LIKE PATHOLOGY AND DEMENTIA IN THE RABBIT (2019) (0)
Oligomer antibodies for Alzheimer’s research, diagnostics and therapeutics (2016) (0)
Amyloid beta-protein (glubulær collection and uses thereof) (1998) (0)
PHS 398/2590 (Rev. 06/09), Biographical Sketch Format Page (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With William L. Klein?

William L. Klein is affiliated with the following schools:

William L. Klein's Academic­Influence.com Rankings